Chronic immune thrombocytopenic purpura in children: Assessment of rituximab treatment
- 28 February 2005
- journal article
- clinical trial
- Published by Elsevier BV in The Journal of Pediatrics
- Vol. 146 (2), 217-221
- https://doi.org/10.1016/j.jpeds.2004.09.004
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpuraBritish Journal of Haematology, 2004
- Rituximab for the treatment of refractory autoimmune hemolytic anemia in childrenBlood, 2003
- Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapsesAnnals of Hematology, 2002
- Treatment of childhood autoimmune haemolytic anaemia with rituximabThe Lancet, 2001
- Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpuraBlood, 2001
- Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-TreatmentJournal of Clinical Oncology, 2000
- Current topic: Idiopathic thrombocytopenic purpuraArchives of Disease in Childhood, 2000
- Rituximab The First Monoclonal Antibody Approved for the Treatment of LymphomaCurrent Pharmaceutical Biotechnology, 2000
- Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology [see comments]Blood, 1996
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood, 1994